News releases

For Johan, 66, shortness of breath and increased sweating were only minor inconveniences, which he quickly dismissed or attributed to external factors. It was only by chance that he discovered during a routine check-up that he had hypertrophic cardiomyopathy (HCM). His journey illustrates how easily this often inherited heart disease can go unnoticed and emphasises the importance of early diagnosis.

At Bristol Myers Squibb, we are committed to raising awareness of HCM, encouraging early detection and advancing research to improve treatment options. Johan’s experience is a powerful reminder of why early diagnosis matters. By supporting patients like him, we constantly strive to improve healthcare and ensure every HCM patient receives the care they need and deserve.

Discover Johan’s story and join us in making a difference for everyone living with HCM.

The outlook for patients with advanced melanoma has significantly improved over the past ten years thanks to innovations in immunotherapy and targeted therapy. During a study day organized by Melanoompunt vzw, experts and survivors discussed the impact of these treatments and the challenges that lie ahead. Despite groundbreaking progress, continued medical innovation remains crucial to further improve survival rates.

Hematologic malignancies are complex, with over 100 types, each requiring a tailored treatment approach. Despite scientific advances in blood cancer treatment, many blood disorders still lack cures or new therapies. BMS is leading innovations in hematology and cell therapy, focusing on personalized care, novel modalities, and patient-centered approaches. With over 25 programs in development, BMS is committed to advancing treatments and improving outcomes for patients, leveraging technologies like AI and fostering collaborations across the healthcare ecosystem.

We have been awarded the esteemed Prix Galien Award for Best Pharmaceutical Agent, recognizing groundbreaking healthcare innovations.

With Bristol Myers Squibb, we celebrated this achievement, often called the "Nobel Prize for medical innovation." This award, originating in France, is now recognized in 15 countries.

Congratulations to all nominees and participants who share our dedication to advancing medical science.

Meet José, a patient who brings to life the daily challenges of living with Hypertrophic Cardiomyopathy (HCM). At Bristol Myers Squibb, we are dedicated to raising awareness and enhancing the management of this often unnoticed inherited heart condition. José's story underscores the critical importance of early diagnosis, ongoing research, and the need for improved treatments.

We invite you to listen carefully to patient experiences and unite with us to create a brighter tomorrow for all affected by this condition.

Every day, we focus on supporting people with psoriasis, one of Europe's most common skin conditions. Psoriasis is more than a skin condition; it is a chronic disease that brings daily challenges and affects both the body and the mind.

In our latest testimonial video, Ann-Sophie from Belgium shares her experiences living with psoriasis. From the daily struggles to her hopes for the medical future. Her story is one of many, but every story is unique and deserves to be heard.

From 16 to 18 September 2023, five Bristol Myers Squibb employees from Belgium and the Netherlands participated in the eighth edition of the Country 2 Country 4 Cancer (C2C4C) bike race. After months of intensive training, they will give their best during three cycling stages from Paris, across Amiens and Calais, to Dover to finish in Uxbridge (London).

On March 8^th, we celebrated International Women’s Day. The focus this year is on gender equity and celebrating women telling their stories. The B-NOW Belgian Chapter was thrilled to invite BMS Braine-l’Alleud-based employees to its first Lunch & Learn session of the year. 

Cancer treatments are getting better, more diverse and more numerous. Although we still die from cancer, we are also increasingly recovering from it... Research, pharmaceutical companies, governments and private individuals are joining forces to fight cancer together.